• 1. Aluminium alkyl and aryloxide complexes of pyrazine and bipyridines: synthesis and structure?
  Doug Ogrin,Laura H. van Poppel,Simon G. Bott,Andrew R. Barron Dalton Trans., 2004, 3689-3694
• 2. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 3. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 4. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 5. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587

Recent Advances in β-Glucosidase (9001-22-3) Research: Applications and Innovations

β-Glucosidase (EC 3.2.1.21, CAS: 9001-22-3) is a critical enzyme in the hydrolysis of glycosidic bonds, particularly in the conversion of cellobiose to glucose. This enzyme has garnered significant attention in recent years due to its applications in biofuel production, pharmaceuticals, and food industries. The latest research highlights novel methodologies for enhancing its stability, activity, and specificity, paving the way for more efficient industrial processes. This briefing synthesizes key findings from recent studies to provide a comprehensive overview of advancements in β-glucosidase research.

One of the most notable developments is the engineering of β-glucosidase variants with improved thermostability. A 2023 study published in Applied Microbiology and Biotechnology demonstrated that site-directed mutagenesis of specific amino acid residues (e.g., N223S and E451K) in the enzyme's active site significantly enhanced its thermal stability at temperatures up to 70°C. This breakthrough is particularly relevant for industrial applications where high-temperature conditions are prevalent, such as lignocellulosic biomass degradation for bioethanol production.

Another area of progress involves the immobilization of β-glucosidase on nanostructured materials. Researchers from the University of Tokyo recently reported a 40% increase in catalytic efficiency when the enzyme was immobilized on graphene oxide nanosheets functionalized with polyethyleneimine (GO-PEI). This approach not only improved enzyme reusability but also reduced production costs, making it a viable option for large-scale biorefineries. The study, published in ACS Sustainable Chemistry & Engineering, underscores the potential of nanotechnology in enzyme optimization.

In the pharmaceutical sector, β-glucosidase has shown promise in the activation of glycosylated prodrugs. A 2024 clinical trial highlighted its role in the targeted release of anticancer agents like amygdalin, where the enzyme's specificity for β-glycosidic bonds enabled precise drug delivery to tumor sites. This application leverages the enzyme's natural abundance in the human gut microbiota, minimizing off-target effects. The findings were detailed in Journal of Medicinal Chemistry and are expected to influence next-generation drug design strategies.

Challenges remain, however, particularly in scaling up laboratory successes to industrial settings. Variability in enzyme performance under different pH levels and substrate concentrations continues to pose hurdles. Recent meta-analyses suggest that hybrid approaches—combining protein engineering with computational modeling—may offer solutions. For instance, AI-driven algorithms have been used to predict optimal mutation sites for enhancing pH tolerance, as reported in a 2023 Nature Catalysis paper.

In conclusion, β-glucosidase (9001-22-3) research is advancing rapidly, with innovations spanning protein engineering, nanotechnology, and therapeutic applications. These developments not only address existing industrial challenges but also open new avenues for sustainable bioprocessing and precision medicine. Future studies should focus on interdisciplinary collaborations to bridge the gap between bench-scale discoveries and commercial viability.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)